The 8 bullish analyst ratings indicate a positive outlook for Zentalis Pharma's stock price. However, the decrease in the average price target from $65.33 to $50.75 suggests that analysts have lowered their expectations for the stock's performance. This could lead to a short-term increase in the stock price, but the lowered expectations may also indicate potential challenges for the company in the future.